Clinical trial · Observational
BAFF and APRIL and RESPONSE TO BELIMUMAB in SLE
B Cell Activating Factor Belonging to the TNF (Tumor Necrosis Factor) Family (BAFF) and a Proliferation-inducing Ligand (APRIL) in Patients With Systemic Lupus Erythematosus: Investigating Biomarkers for the Response to the Belimumab Treatment
NCT03919643CI-TRIAL-00038236BAFFunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project is intended to identify the routes on which BAFF and APRIL act in order to detect possible future candidates to Belimumab treatment among patients diagnosed of SLE.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BAFF Polymorphism | — | UNRESOLVED | — |
| Systemic Lupus Erythematosus | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- SLE patients with nephritis
- description
- No intervention. Peripheral blood and urine samples will be obtained
- label
- SLE patients with without nephritis
- description
- No intervention. Peripheral blood and urine samples will be obtained
- label
- Healthy controls (blood donors)
- description
- No intervention. Peripheral blood and urine samples will be obtained
Primary outcomes (3)
- measure
- Improve knowledge of B Cell activating factor belonging to the TNF (Tumor necrosis factor) family (BAAF) system in order to identify those SLE (Systemic Lupus Erythematous) patients that are candidate for treatment with anti-BAFF.
- timeFrame
- from data of Informed consent form signature to finish of follow-up (1 Year)
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion criteria * Women18-60 years old * For patients only treated with conventional drugs (without immunosuppressive or biological treatment ) * For Healthy controls: no autoimmune diseases (blood donors) diagnoses
References
Publications (1)
- DERIVEDOrtiz-Aljaro P, Montes-Cano MA, Garcia-Lozano JR, Aquino V, Carmona R, Perez-Florido J, Garcia-Hernandez FJ, Dopazo J, Gonzalez-Escribano MF. Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus. Sci Rep. 2022 Jul 2;12(1):11219. doi: 10.1038/s41598-022-15549-0. PMID 35780200